Pharmacogenomics of Age-Specific, Asparaginase-Induced Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia
Description
Brief Summary
This pilot trial studies the impact of genetic information on developing liver damage caused
by asparaginase in participants with newly diagnosed acute lymphoblastic leukemia. Testing
saliva samples may help doctors find certain genetic markers that may predict whether
participants will tolerate asparaginase, which is given as part of clinical care for acute
lymphoblastic leukemia.
Detailed Description
I. To establish the association between the SOD2 rs4880 genotypes and asparaginase-induced
hepatotoxicity in Hispanic patients.
II. To identify novel single nucleotide polymorphisms (SNPs) that are associated with
asparaginase induced hepatotoxicity.
OUTLINE:
Participants' SOD2 rs4880 SNP genotype (based on saliva from buccal swabs) will be
classified. Participants with the CC genotype will be compared to participants with the CT or
TT genotype. Buccal swabs of prospective participants' saliva will be collected when
participant achieves complete remission (during regular clinical visit). Retrospective
participants will be identified through search of pharmacy records for those who received
asparaginase within the last 5 years (2012-2017). Recurrent patients will be consented during
their regular clinical visits and samples will be collected.
Phase
N/AInclusion and Exclusion Criteria
- Newly diagnosed with acute lymphoblastic leukemia (ALL)
- no prior treatment for ALL
- Receiving asparaginase as part of the primary treatment regimen
- Ability to understand and the willingness to sign a written informed consent
- For retrospective recruitment, those who have received asparaginase between 2012 and 2017; and are current patients of University of Southern California (USC)
- Patients who are unable to give informed consent
Sites
Please contact the trial administrator to learn more about where you can participate in this trial. Please use the contact form on the right side.